Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Burkitt Lymphoma 12Lymphoma, Follicular 8Lymphoma, Non-Hodgkin 6Lymphoma 6Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Triple Negative Breast Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoma, Mantle-Cell 1Lymphadenopathy 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Hairy Cell 1

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × Prednisone × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡